In EGFR-mutant lung cancers, targeting aldo-keto reductase family 1 member B1 (AKR1B1), a key upstream regulatory protein of xCT that is upregulated in all resistant cell models, overcomes resistance to several TKIs by blocking cystine uptake and GSH accumulation [145]. This evidence concerns the gene AKR1B1 and lung carcinoma.